Insulin degludec (IDeg) is a long-acting basal insulin recently developed for use in humans. It is increasingly being used in diabetes due to its favourable efficacy and safety profile. Insulin degLudec has a smooth time/action profile over more than 42h.
| Excerpt | Reference | Relevance |
|---|
| "Insulin degludec (IDeg) is a long-acting basal insulin recently developed for use in humans. " | ( The effect of Insulin Degludec on glycemic control in diabetic cats over a 12-month period.
Mori, A; Oda, H; Sako, T, 2020) | 2.36 |
| "Insulin degludec is an ultra-long-acting insulin analogue that is increasingly being used in diabetes due to its favourable efficacy and safety profile. " | ( Rapid quantification of insulin degludec by immunopurification combined with liquid chromatography high-resolution mass spectrometry.
Antwi, K; Bally, L; Groessl, M; Nakas, CT; Niederkofler, EE; Prost, JC; Reverter-Branchat, G, 2020) | 2.31 |
| "Insulin degludec (IDeg) is an ultra-long-acting insulin that has a smooth time/action profile over more than 42h. " | ( Effect of insulin degludec versus insulin glargine on glycemic control and daily fasting blood glucose variability in insulin-naïve Japanese patients with type 2 diabetes: I'D GOT trial.
Aso, Y; Chiba, Y; Fujita, N; Kuroda, H; Murano, S; Sato, M; Suzuki, K; Takada, Y, 2017) | 2.3 |
| "Insulin degludec (IDeg) is a new insulin formulation that facilitates long-term control of glucose level in humans. " | ( Time-action profiles of insulin degludec in healthy dogs and its effects on glycemic control in diabetic dogs.
Ishii, S; Mori, A; Oda, H; Onozawa, E; Sako, T; Shono, S, 2018) | 2.23 |
| "Insulin degludec is a new ultra-long-action basal insulin. " | ( Current status of insulin degludec in type 1 and type 2 diabetes based on randomized and observational trials.
Buysschaert, M; Preumont, V, 2020) | 2.33 |
| "Insulin degludec (Tresiba(®)) is an ultra-long-acting insulin analogue that is also available as a coformulation with rapid-acting insulin aspart (insulin degludec/insulin aspart) [Ryzodeg(®)]. " | ( Insulin degludec and insulin degludec/insulin aspart: a review of their use in the management of diabetes mellitus.
Keating, GM, 2013) | 3.28 |
| "Insulin degludec (IDeg) is a new-generation basal insulin that forms soluble multi-hexamers upon subcutaneous injection, resulting in a depot from which IDeg monomers are slowly and continuously absorbed to provide an ultra-long action profile. " | ( A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec.
Adrian, CL; Deller, S; Haahr, H; Koehler, G; Korsatko, S; Mader, JK; Neubauer, K; Pieber, TR; Thomsen, H, 2013) | 2.04 |
| "Insulin degludec (IDeg) is a new basal insulin in development with a flat, ultra-long action profile that may permit dosing using a simplified titration algorithm with less frequent self-measured blood glucose (SMBG) measurements and more simplified titration steps than currently available basal insulins." | ( Insulin degludec once-daily in type 2 diabetes: simple or step-wise titration (BEGIN: once simple use).
Brod, M; Niemeyer, M; Ocampo Francisco, AM; Philis-Tsimikas, A; Rothman, J, 2013) | 3.28 |
| "Insulin degludec is a new basal insulin analogue with an ultra-long duration of action that provides a flat and stable action profile with a duration of action greater than 42 hours. " | ( Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes.
Gouet, D; Kerlan, V; Marre, M; Renard, É, 2013) | 2.29 |
| "Insulin degludec is a new-generation basal insulin with an ultra-long duration of action. " | ( Insulin degludec: pharmacokinetics in patients with renal impairment.
Arold, G; Bøttcher, SG; Haahr, H; Kiss, I; Klim, S; Roepstorff, C, 2014) | 3.29 |
| "Insulin degludec is a basal insulin with a slow and distinct absorption mechanism resulting in an ultra-long, flat, and stable pharmacokinetic profile in patients with diabetes mellitus. " | ( Insulin degludec: pharmacokinetic properties in subjects with hepatic impairment.
Arold, G; Haahr, H; Højbjerre, M; Klim, S; Kupčová, V; Roepstorff, C, 2014) | 3.29 |
| "Insulin degludec (IDeg) is a basal insulin with an ultra-long pharmacokinetic profile in adults that at steady-state produces remarkably flat and stable insulin levels; however, no studies have yet reported on the pharmacokinetic properties of IDeg in subjects younger than 18 years of age. " | ( Insulin degludec's ultra-long pharmacokinetic properties observed in adults are retained in children and adolescents with type 1 diabetes.
Aschemeier, B; Biester, T; Blaesig, S; Danne, T; Granhall, C; Haahr, H; Kordonouri, O; Kristensen, NR; Remus, K; Søndergaard, F, 2014) | 3.29 |
| "Insulin degludec (IDeg) is a new basal insulin with an ultra-long and stable glucose-lowering effect. " | ( Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-naïve patients with type 2 diabetes.
Cariou, B; Handelsman, Y; Mathieu, C; Rana, A; Rodbard, HW; Wolden, ML; Zinman, B, 2014) | 2.12 |
| "Insulin degludec (IDeg) is a basal insulin with an ultralong duration of action and a flat and stable glucose-lowering effect profile." | ( Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type 2 diabetes mellitus.
Haahr, H; Hompesch, M; Morrow, L; Roepstorff, C; Thomsen, HF; Watkins, E, 2014) | 1.38 |
| "Insulin degludec is a desB30 insulin acylated at the LysB29 residue with a glutamate linker and 16-carbon fatty diacyl side chain." | ( The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?
Capuano, A; Esposito, K; Giugliano, D; Maiorino, MI; Petrizzo, M, 2014) | 1.12 |
| "Insulin degludec (IDeg) is a new-generation basal insulin with an ultra-long duration of action. " | ( A review of the pharmacological properties of insulin degludec and their clinical relevance.
Haahr, H; Heise, T, 2014) | 2.1 |
| "Insulin degludec is a new-generation basal insulin with an ultra-long duration of action. " | ( Treating to target in type 2 diabetes: the BEGIN trial programme.
Chowdhury, S; Rao, PV; Wangnoo, SK, 2014) | 1.85 |
| "Insulin degludec (IDeg) is a basal insulin with a stable, flat action profile and an even distribution of the blood glucose lowering effect over 24 hou rs. " | ( [Daytime flexible application of Insulin degludec in patients with type 1 diabetes or type 2 diabetes].
Jaeckel, E; Lüdemann, J; Milek, K; Segner, A; Wilhelm, B, 2014) | 2.13 |
| "Insulin degludec is a new-generation ultra-long-acting basal insulin which offers a significantly more predictable glucose-lowering effect than other long-acting insulin analogues. " | ( The beneficial effect of insulin degludec on nocturnal hypoglycaemia and insulin dose in type 1 diabetic patients: a systematic review and meta-analysis of randomised trials.
Dżygało, K; Golicki, D; Kowalska, A; Szypowska, A, 2015) | 2.16 |
| "Insulin degludec (IDeg) is a basal insulin with a stable, flat action profile and an even distribution of the blood glucose lowering effect over 24 hou rs. " | ( [Daytime flexible application of Insulin degludec in patients with type 1 diabetes or type 2 diabetes].
Jaeckel, E; Lüdemann, J; Milek, K; Segner, A; Wilhelm, B, 2014) | 2.13 |
| "Insulin degludec (IDeg) is a novel basal insulin with improved pharmacokinetic and pharmacodynamic properties compared to insulin glargine (IGlar) including a long half-life of ∼25 h and a duration of action >42 h at steady state, providing a flat and stable blood glucose-lowering effect when injected once daily." | ( Clinical use of insulin degludec.
Cariou, B; Evans, M; Gross, JL; Harris, S; Landstedt-Hallin, L; Meneghini, L; Mithal, A; Rodriguez, MR; Vora, J, 2015) | 1.48 |
| "Insulin degludec (IDeg) is a new basal insulin that forms soluble multihexamers after subcutaneous injection resulting in an ultra-long duration of action and stable glucose-lowering effect." | ( Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials.
Del Prato, S; Diamant, M; Gall, MA; Niemeyer, M; Russell-Jones, D, 2015) | 2.58 |
| "Insulin degludec is an insulin analog with an ultra-long duration of action that exhibits less intra-patient variability in its glucose-lowering activity, and reduces nocturnal, overall, and severe hypoglycemia relative to insulin glargine. " | ( A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.
Pollock, RF; Tikkanen, CK, 2017) | 2.17 |
| "Insulin degludec (IDeg) is a long-acting basal human insulin analog produced using recombinant DNA technology. " | ( An Evolutionary Perspective on Basal Insulin in Diabetes Treatment: Innovations in Insulin: Insulin Degludec U-100 and U-200.
Philis-Tsimikas, A, 2016) | 2.1 |
| "Insulin degludec (IDeg) is a basal insulin that forms soluble multihexamers after subcutaneous injection, resulting in an ultra-long action profile. " | ( Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.
Birkeland, KI; DeVries, JH; Endahl, LA; Home, PD; Jendle, JH; Johansen, T; Lyby, K; Meneghini, LF; Ratner, RE; Roberts, AP; Wendisch, U, 2011) | 3.25 |
| "Insulin degludec is a new, ultra-longacting basal insulin." | ( Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Bode, B; Buse, J; Fisher, M; Francisco, AM; Garg, S; Heller, S; Marre, M; Merker, L; Pei, H; Philotheou, A; Renard, E; Russell-Jones, D, 2012) | 2.54 |
| "Insulin degludec is a new, ultra-longacting basal insulin." | ( Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Balci, MK; Del Prato, S; Endahl, LA; Francisco, AM; Garber, AJ; Hollander, P; King, AB; Muñoz-Torres, M; Rosenstock, J; Sreenan, S, 2012) | 2.54 |
| "Insulin degludec (IDeg) is a new-generation basal insulin with an ultra-long duration of action. " | ( Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes.
Feldman, A; Haahr, H; Heise, T; Hermanski, L; Nosek, L; Rasmussen, S, 2012) | 3.26 |
| "Insulin degludec (IDeg) is a new-generation, ultra-long-acting basal insulin that forms soluble multihexamers upon subcutaneous injection, resulting in a depot from which IDeg is absorbed slowly and continuously into circulation. " | ( Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes.
Bøttcher, SG; Haahr, H; Hastrup, H; Heise, T; Nosek, L, 2012) | 2.16 |
| "Insulin degludec is an ultra-long-acting basal insulin analogue that possesses a flat, stable glucose-lowering effect in patients with type 1 or type 2 diabetes mellitus." | ( Can a new ultra-long-acting insulin analogue improve patient care? Investigating the potential role of insulin degludec.
Campbell, RK; Neumiller, JJ; Robinson, JD, 2012) | 1.32 |
| "Insulin degludec is a novel acylated basal insulin with a unique mechanism of protracted absorption involving the formation of a depot of soluble multihexamer chains after subcutaneous injection." | ( Insulin degludec: overview of a novel ultra long-acting basal insulin.
Davies, M; Gough, SC; Harris, S; Woo, V, 2013) | 2.55 |
| "Insulin degludec is a novel, ultra-long-acting basal insulin analogue that has a similar safety and efficacy profile when compared with insulin glargine in patients with type 1 or type 2 diabetes. " | ( Insulin degludec: a novel basal insulin analogue.
Goldman-Levine, JD; Patel, DK; Schnee, DM, 2013) | 3.28 |
Insulin degludec has a flat, stable glucose-lowering profile with a duration of action of >42 h. It has less within-patient day-to-day variability than the long-acting insulin analogue insulin glargine.
Insulin degludec has been extensively studied in the BEGIN programme in a range of patients with type 1 or type 2 diabetes. It has been associated with slightly less weight gain and fewer nocturnal hypoglycaemic episodes when compared with insulin glargine.
IdegLira was generally well tolerated. The combined use of a basal insulin (insulin degludec) with an AR-GLP1 (liraglutide) is proposed as an effective and safe therapeutic alternative.
| Excerpt | Reference | Relevance |
|---|
| " Adverse event profiles were similar across groups." | ( The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individ
Atkin, SL; Bain, S; Begtrup, K; Birkeland, KI; Blonde, L; Gough, SC; Johansen, T; Meneghini, L; Raz, I; Shestakova, M, 2013) | 0.69 |
| " Adverse event profiles were similar between groups." | ( Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial.
Bantwal, G; Davies, MJ; Gall, MA; Gross, JL; Niemeyer, M; Ono, Y; Sasaki, T; Seino, H, 2014) | 0.71 |
| " IDegLira was generally well tolerated; fewer participants in the IDegLira group than in the liraglutide group reported gastrointestinal adverse events (nausea 8·8 vs 19·7%), although the insulin degludec group had the fewest participants with gastrointestinal adverse events (nausea 3·6%)." | ( Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 di
Bode, B; Buse, JB; Damgaard, LH; Gough, SC; Linjawi, S; Poulsen, P; Rodbard, HW; Woo, V, 2014) | 0.84 |
| " On the other hand, hypoglycaemia may generate adverse effects and disease complications, will compromise the quality of life and will substantially increase the economic burden of treatment budged." | ( Understanding the safety of the new ultra long acting basal insulin.
Gupta, V; Kalra, S; Kesavadev, J; Ramachandran, A, 2014) | 0.4 |
| " Both treatments were well tolerated with comparable rates of adverse events." | ( Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes.
Danne, T; Deeb, L; Iotova, V; Kawamura, T; Kinduryte, O; Klingensmith, G; Ocampo Francisco, AM; Philotheou, A; Silverstein, J; Thalange, N; Tumini, S, 2015) | 1.86 |
| " Overall, all treatments were well tolerated and no new adverse events or tolerability issues were observed for IDegLira." | ( One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial.
Bode, BW; Buse, JB; Gough, SC; Linjawi, S; Reiter, PD; Rodbard, HW; Woo, VC; Zacho, M, 2015) | 0.66 |
| " The rates of adverse events with IDeg flexible and IDeg fixed dosing were similar." | ( Efficacy and safety of once-daily insulin degludec dosed flexibly at convenient times vs fixed dosing at the same time each day in a Japanese cohort with type 2 diabetes: A randomized, 26-week, treat-to-target trial.
Hersløv, ML; Hyllested-Winge, J; Jinnouchi, H; Kadowaki, T; Kaku, K; Nakamura, S, 2016) | 0.71 |
| " There was no significant difference in the incidence rate of adverse events in two groups (OR=0." | ( [Efficacy and safety of insulin degludec for diabetes mellitus: a meta-analysis].
Deng, XR; Ding, L; Jing, CB; Liu, HX; Sun, SM; Wang, YF; Zheng, RZ, 2016) | 0.74 |
| " Rates of adverse events did not differ between the two groups." | ( Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
Brown-Frandsen, K; Buse, JB; Emerson, SS; Haahr, PM; Kvist, K; Lange, M; Marso, SP; McGuire, DK; Moses, A; Pieber, TR; Poulter, NR; Pratley, RE; Skibsted, S; Zinman, B, 2017) | 0.46 |
| " The rates of adverse events including total mortality and cardiovascular events were not significantly different between two treatment strategies." | ( Comparative safety and efficacy of insulin degludec with insulin glargine in type 2 and type 1 diabetes: a meta-analysis of randomized controlled trials.
Kang, LN; Xu, B; Zhang, XL; Zhang, XW, 2018) | 0.76 |
| "A total of 150 first major adverse cardiovascular events were recorded at cut-off for the interim analysis." | ( Developing, Planning and Conducting an Interim Analysis: Lessons From the DEVOTE Cardiovascular Outcomes Trial (Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascul
Amby, LK; Endahl, L; Helmark, IC; Hoskin, S; Hvelplund, A; Mollerup, I; Moses, AC; Theilgaard, H, 2019) | 0.71 |
| " Therefore, the combined use of a basal insulin (insulin degludec) with an AR-GLP1 (liraglutide), in a single device (IdegLira), is proposed as an effective and safe therapeutic alternative for the treatment intensification in people with type 2 diabetes." | ( [Efficacy and safety of IdegLira for the intensification of type 2 diabetes treatment].
Costa Gil, JE; Faingold, MC; Fuente, GV; Litwak, LE; Rodríguez, M, ) | 0.39 |
| " Outcomes by overall age group and randomized treatment differences were analysed for major adverse cardiovascular events (MACE), all-cause mortality, severe hypoglycaemia and serious adverse events (SAEs)." | ( Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7).
Buse, JB; Emerson, SS; Franek, E; Gilbert, MP; Hansen, CT; Hansen, MV; Mark, T; Marso, SP; McGuire, DK; Moses, AC; Pieber, TR; Pratley, RE; Zinman, B, 2019) | 0.76 |
| "This study aimed to compare the rate of hypoglycemic events from all spontaneously reported adverse events (AEs) between insulin detemir and insulin degludec using the Korea Adverse Event Reporting System (KAERS) database." | ( Disproportionality analysis of spontaneously reported hypoglycemia events due to insulin use: A comparison between insulin detemir and insulin degludec using the Korea Adverse Event Reporting System.
Jeong, D; Kim, W; Shin, JY, 2021) | 1.03 |
| "We analyzed data on the reported hypoglycemia events retrieved from adverse drug reactions (ADR) on the use of different insulin types from 2016 to 2017 in the Korea Institute of Drug Safety & Risk Management-Korea Adverse Event Reporting System Database (KIDS-KD)." | ( Disproportionality analysis of spontaneously reported hypoglycemia events due to insulin use: A comparison between insulin detemir and insulin degludec using the Korea Adverse Event Reporting System.
Jeong, D; Kim, W; Shin, JY, 2021) | 0.82 |
| " One year after initiating IDegAsp, incidence of adverse events (AEs [primary endpoint]), serious AEs, adverse drug reactions (ADRs), and severe hypoglycaemia (secondary safety endpoints) were assessed in the safety analysis set (SAS)." | ( Long-Term Safety and Clinical Outcomes with Insulin Degludec/Insulin Aspart Treatment in Japanese Patients with Diabetes: A Real-World, Prospective, Observational Study.
Eriksen, KT; Ishigaki, Y; Katabami, T; Yamamoto, Y, 2022) | 0.98 |
| " Thirty adverse events were reported in 23 patients (2." | ( Safety of Insulin Degludec/Insulin Aspart in Patients with Diabetes Mellitus over a Period of 1 Year during Routine Clinical Care in India: SMART (Study of Management of Diabetes with Ryzodeg™ Treatment).
Asirvatham, A; Basu, D; Gowda, A; Kesavadev, J; Kumar, H; Lodha, S; Mukherjee, JJ; Pathan, MK; Revanna, M; Shah, N; Singh, KP; Yalamanchi, SR, 2021) | 1.02 |
| " The results showed that IDeg/Asp significantly decreased the mean hemoglobin A1c (HbA1c) level but was prone to serious adverse events, and IGlar increased the nocturnal confirmed hypoglycemia events." | ( Comparative efficiency and safety of insulin degludec/aspart with insulin glargine in type 2 diabetes: a meta-analysis of randomized controlled trials.
Huang, JS; Lai, JM; Lai, YM; Li, SZ; Lin, JT; Lin, MH; Long, T; Wu, QL; Zeng, CP; Zeng, JY; Zhou, ZC, 2022) | 0.99 |
| "Treatment with degludec U100 is as effective and safe as glargine U300 for the early postoperative hospital management of patients with T2D undergoing CABG." | ( Efficacy and safety of degludec U100 versus glargine U300 for the early postoperative management of patients with type 2 diabetes mellitus undergoing coronary artery bypass graft surgery: A non-inferiority randomized trial.
Gagneja, S; Gill, HK; Jain, R; Kaur, P; Kohli, C; Kuchay, MS; Kumari, P; Mathew, A; Mishra, M; Mishra, SK; Singh, MK; Surendran, P; Wasir, JS, 2023) | 0.91 |
| " Occurrence of serious adverse events was similar between the BIF and degludec groups." | ( Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes.
Bue-Valleskey, JM; Chien, J; Chigutsa, E; Dahl, D; Haupt, A; Kazda, CM; Landschulz, W; Wullenweber, P; Zhang, Q, 2023) | 1.12 |
Insulin degludec (IDeg) is a basal insulin with an ultra-long pharmacokinetic profile in adults that at steady-state produces remarkably flat and stable insulin levels.
| Excerpt | Reference | Relevance |
|---|
| " We compared the pharmacodynamic (PD) variability of IDeg and insulin glargine (IGlar) under steady-state conditions." | ( Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes.
Feldman, A; Haahr, H; Heise, T; Hermanski, L; Nosek, L; Rasmussen, S, 2012) | 1.82 |
| " This double-blind, crossover, randomized study compared the pharmacokinetic and pharmacodynamic properties between IDeg 100 U/mL (U100) and IDeg 200 U/mL (U200) under steady-state (SS) conditions in subjects with type 1 diabetes mellitus." | ( A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec.
Adrian, CL; Deller, S; Haahr, H; Koehler, G; Korsatko, S; Mader, JK; Neubauer, K; Pieber, TR; Thomsen, H, 2013) | 0.59 |
| "IDeg U100 and U200 formulations are bioequivalent and have similar pharmacodynamic profiles at SS, implying that they can be used interchangeably in clinical practice." | ( A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec.
Adrian, CL; Deller, S; Haahr, H; Koehler, G; Korsatko, S; Mader, JK; Neubauer, K; Pieber, TR; Thomsen, H, 2013) | 0.59 |
| " There is a continuous and highly predictable slow dissociation of insulin monomers from this depot; insulin levels rise immediately reaching tmax at 10-12 hours, followed by a slow decline with a t½ of 17-21 hours, roughly double the duration of action of insulin glargine." | ( Insulin degludec: a long-acting modern insulin analogue with a predictable pharmacokinetic/pharmacodynamic profile.
Rendell, M, 2013) | 1.83 |
| " We evaluated the pharmacokinetic properties of insulin degludec in subjects with normal renal function; mild, moderate or severe renal impairment; or end-stage renal disease (ESRD) undergoing hemodialysis." | ( Insulin degludec: pharmacokinetics in patients with renal impairment.
Arold, G; Bøttcher, SG; Haahr, H; Kiss, I; Klim, S; Roepstorff, C, 2014) | 2.1 |
| "The ultra-long pharmacokinetic properties of insulin degludec were preserved in subjects with renal impairment, with no statistically significant differences in absorption or clearance, compared with subjects with normal renal function." | ( Insulin degludec: pharmacokinetics in patients with renal impairment.
Arold, G; Bøttcher, SG; Haahr, H; Kiss, I; Klim, S; Roepstorff, C, 2014) | 2.1 |
| "The aim of this study was to evaluate the pharmacokinetic and pharmacodynamic properties of insulin degludec (IDeg), a basal insulin with an ultra-long duration of action, in elderly subjects with type 1 diabetes compared with younger adults." | ( Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitus.
Deller, S; Glettler, K; Haahr, H; Hastrup, H; Koehler, G; Korsatko, S; Mader, JK; Pieber, TR; Søndergaard, F; Treiber, G; Urschitz, M; Wolf, M, 2014) | 0.89 |
| " Following 6-day dosing, a 26-hour euglycaemic glucose clamp procedure was conducted to evaluate the steady-state pharmacodynamic effects of IDeg." | ( Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitus.
Deller, S; Glettler, K; Haahr, H; Hastrup, H; Koehler, G; Korsatko, S; Mader, JK; Pieber, TR; Søndergaard, F; Treiber, G; Urschitz, M; Wolf, M, 2014) | 0.67 |
| " The ultra-long pharmacokinetic and pharmacodynamic properties of IDeg observed in younger adults were preserved in elderly subjects with type 1 diabetes." | ( Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitus.
Deller, S; Glettler, K; Haahr, H; Hastrup, H; Koehler, G; Korsatko, S; Mader, JK; Pieber, TR; Søndergaard, F; Treiber, G; Urschitz, M; Wolf, M, 2014) | 0.67 |
| "Insulin degludec is a basal insulin with a slow and distinct absorption mechanism resulting in an ultra-long, flat, and stable pharmacokinetic profile in patients with diabetes mellitus." | ( Insulin degludec: pharmacokinetic properties in subjects with hepatic impairment.
Arold, G; Haahr, H; Højbjerre, M; Klim, S; Kupčová, V; Roepstorff, C, 2014) | 3.29 |
| " Blood samples up to 120 h post-dose and fractionated urine samples were collected to measure pharmacokinetic parameters." | ( Insulin degludec: pharmacokinetic properties in subjects with hepatic impairment.
Arold, G; Haahr, H; Højbjerre, M; Klim, S; Kupčová, V; Roepstorff, C, 2014) | 1.85 |
| "No difference was observed in pharmacokinetic parameters [area under the 120-h serum insulin degludec concentration-time curve (AUC120 h), maximum insulin degludec concentration (C max), and apparent clearance (CL/F)] for subjects with impaired versus normal hepatic function after a single dose of insulin degludec." | ( Insulin degludec: pharmacokinetic properties in subjects with hepatic impairment.
Arold, G; Haahr, H; Højbjerre, M; Klim, S; Kupčová, V; Roepstorff, C, 2014) | 2.07 |
| "The ultra-long pharmacokinetic properties of insulin degludec were preserved in subjects with hepatic impairment and there were no statistically significant differences in absorption or clearance compared with subjects with normal hepatic function." | ( Insulin degludec: pharmacokinetic properties in subjects with hepatic impairment.
Arold, G; Haahr, H; Højbjerre, M; Klim, S; Kupčová, V; Roepstorff, C, 2014) | 2.1 |
| "Insulin degludec (IDeg) is a basal insulin with an ultra-long pharmacokinetic profile in adults that at steady-state produces remarkably flat and stable insulin levels; however, no studies have yet reported on the pharmacokinetic properties of IDeg in subjects younger than 18 years of age." | ( Insulin degludec's ultra-long pharmacokinetic properties observed in adults are retained in children and adolescents with type 1 diabetes.
Aschemeier, B; Biester, T; Blaesig, S; Danne, T; Granhall, C; Haahr, H; Kordonouri, O; Kristensen, NR; Remus, K; Søndergaard, F, 2014) | 3.29 |
| "Pharmacokinetic and pharmacodynamic profiles of exogenous insulin may be affected by intrinsic factors, such as age, ethnicity/race, and hepatic and renal function." | ( Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type 2 diabetes mellitus.
Haahr, H; Hompesch, M; Morrow, L; Roepstorff, C; Thomsen, HF; Watkins, E, 2014) | 0.66 |
| "The purpose of this study was to investigate whether the pharmacokinetic and pharmacodynamic responses to IDeg at steady state vary according to patient race/ethnicity." | ( Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type 2 diabetes mellitus.
Haahr, H; Hompesch, M; Morrow, L; Roepstorff, C; Thomsen, HF; Watkins, E, 2014) | 0.66 |
| " Differences in pharmacokinetic and pharmacodynamic variables among groups were analyzed using an ANOVA with treatment period, an interaction between race/ethnicity, and treatment as fixed factors, subject as a random effect, and residual variance, depending on treatment." | ( Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type 2 diabetes mellitus.
Haahr, H; Hompesch, M; Morrow, L; Roepstorff, C; Thomsen, HF; Watkins, E, 2014) | 0.66 |
| "The similar pharmacokinetic and pharmacodynamic responses to IDeg in 3 racial/ethnic groups of patients with type 2 diabetes mellitus suggest that the flat, stable, and ultralong pharmacokinetic and pharmacodynamic profiles of IDeg are preserved irrespective of race/ethnicity." | ( Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type 2 diabetes mellitus.
Haahr, H; Hompesch, M; Morrow, L; Roepstorff, C; Thomsen, HF; Watkins, E, 2014) | 0.66 |
| " Glucose infusion rate (GIR), distribution of GIR and half-life were assessed." | ( Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
Bøttcher, SG; Haahr, H; Heise, T; Hermanski, L; Hövelmann, U; Nosek, L, 2015) | 0.65 |
| " At SS, the half-life was 25." | ( Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
Bøttcher, SG; Haahr, H; Heise, T; Hermanski, L; Hövelmann, U; Nosek, L, 2015) | 0.65 |
| "IDeg has a longer half-life (> 25 h) than IGlar." | ( Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
Bøttcher, SG; Haahr, H; Heise, T; Hermanski, L; Hövelmann, U; Nosek, L, 2015) | 0.65 |
| "The present study aimed to evaluate the pharmacokinetic and pharmacodynamic properties of insulin degludec (IDeg) in Japanese patients with type 1 diabetes." | ( Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patients.
Bardtrum, L; Haahr, H; Hirao, K; Ikushima, I; Kaku, K, 2016) | 0.91 |
| " Blood samples for pharmacokinetic measurements were obtained before each dose and up to 120 h after the last dose of each treatment period." | ( Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patients.
Bardtrum, L; Haahr, H; Hirao, K; Ikushima, I; Kaku, K, 2016) | 0.69 |
| " Overall, the pharmacodynamic and pharmacokinetic end-points and safety observations are consistent with those previously reported in Caucasian patients." | ( Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patients.
Bardtrum, L; Haahr, H; Hirao, K; Ikushima, I; Kaku, K, 2016) | 0.69 |
| "Available pharmacokinetic data, clinical trials and abstracts regarding fixed-ratio combination of insulin degludec and liraglutide were reviewed." | ( Pharmacokinetic evaluation of fixed-ratio combination of insulin degludec and liraglutide in the treatment of type 2 diabetes.
Davis, SN; Lamos, EM, 2016) | 0.9 |
| " The pharmacokinetic and pharmacodynamic characteristics of IDegAsp have been investigated in a series of clinical pharmacology studies with generally comparable designs, methodologies and patient inclusion/exclusion criteria." | ( A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use.
Fita, EG; Haahr, H; Heise, T, 2017) | 0.83 |
| " Pharmacodynamic variables were assessed at steady-state from the glucose infusion rate profiles of three 24-hour euglycaemic glucose clamps (days 6, 9 and 12) during each treatment period." | ( Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes.
Famulla, S; Haahr, HL; Heise, T; Kaplan, K; Nosek, L; Nørskov, M, 2017) | 1.9 |
| "To compare steady state pharmacodynamic and pharmacokinetic profiles of insulin glargine 300U/mL (Gla-300) with insulin degludec 100U/mL (Deg-100) in people with type 1 diabetes." | ( Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes.
Bailey, TS; Bolli, GB; Dahmen, R; Klein, O; Maroccia, M; Nassr, N; Pettus, J; Roussel, R; Schmider, W, 2018) | 0.89 |
| "Gla-300 provides less fluctuating steady state pharmacodynamic profiles (i." | ( Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes.
Bailey, TS; Bolli, GB; Dahmen, R; Klein, O; Maroccia, M; Nassr, N; Pettus, J; Roussel, R; Schmider, W, 2018) | 0.68 |
| "With the aim to improve current therapeutic and monitoring options for diabetic cats, the present study compared pharmacodynamic parameters of protamine zinc insulin (PZI) and insulin degludec and validated the continuous glucose monitoring system (CGMS) iPro2 with Sof-sensor and Enlite-sensor focusing on the low glycemic range." | ( Comparison of the pharmacodynamics of protamine zinc insulin and insulin degludec and validation of the continuous glucose monitoring system iPro2 in healthy cats.
Lutz, TA; Reusch, CE; Riederer, A; Salesov, E; Zini, E, 2018) | 0.91 |
| "4 U/kg, morning) showed a more stable pharmacodynamic profile (20% lower within-day variability [P = 0." | ( Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation.
Bolli, GB; Fanelli, CG; Owens, DR; S Bailey, T; Yale, JF, 2019) | 0.75 |
| " Furthermore, we report a population pharmacokinetic analysis of a 26-week, phase III, treat-to-target, randomized trial of 720 Chinese individuals with type 2 diabetes." | ( Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population.
Chen, X; Hu, P; Ingwersen, SH; Jia, T; Liu, H; Luo, B; Vestergård Jacobsen, L, 2022) | 0.97 |
| "B01411 exhibited a pharmacokinetic and pharmacodynamic similarity to the reference product." | ( A phase-I randomized euglycemic clamp study to demonstrate the pharmacokinetic and pharmacodynamic equivalence of an insulin degludec biosimilar (B01411) with the reference product in healthy Chinese volunteers.
Chen, X; Jia, D; Li, J; Li, T; Liu, H; Tan, H; Yu, H; Yu, Y, ) | 0.34 |
Dulaglutide combined with insulin degludec significantly reduces glucose fluctuations in patients with type 2 diabetes mellitus and improves the TIR rate.
Insulin degludec may provide dosing options for patients who require some flexibility in adhering to an insulin regimen. It may also reduce the risk of hypoglycemia compared with the basal insulins that are currently available.
| Excerpt | Relevance | Reference |
|---|
| "Insulin degludec may provide dosing options for patients who, because of their lifestyle, require some flexibility in adhering to an insulin regimen, and it may also reduce the risk of hypoglycemia compared with the basal insulins that are currently available." | ( Insulin degludec--a new-generation basal insulin.
Atkin, SL; Wakil, A, 2012) | 3.26 |
| " Once-daily dosing produces a steady-state profile characterized by a near-constant effect, which varies little from injection to injection in a given patient." | ( Insulin degludec: overview of a novel ultra long-acting basal insulin.
Davies, M; Gough, SC; Harris, S; Woo, V, 2013) | 1.83 |
| " Participants were randomized to 1) once-daily (OD) IDeg in a prespecified dosing schedule, creating 8-40-h intervals between injections (IDeg OD Flex; n = 229); 2) once-daily IDeg at the main evening meal (IDeg OD; n = 228); or 3) once-daily insulin glargine at the same time each day (IGlar OD; n = 230)." | ( The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individ
Atkin, SL; Bain, S; Begtrup, K; Birkeland, KI; Blonde, L; Gough, SC; Johansen, T; Meneghini, L; Raz, I; Shestakova, M, 2013) | 0.69 |
| "The use of extreme dosing intervals of 8-40 h demonstrates that the daily injection time of IDeg can be varied without compromising glycemic control or safety." | ( The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individ
Atkin, SL; Bain, S; Begtrup, K; Birkeland, KI; Blonde, L; Gough, SC; Johansen, T; Meneghini, L; Raz, I; Shestakova, M, 2013) | 0.69 |
| " Because of its peakless, extended and highly predictable glucose-lowering effect, once-daily dosing on a flexible schedule may be feasible with degludec." | ( Flexibly timed once-daily dosing with degludec: a new ultra-long-acting basal insulin.
Josse, RG; Woo, V, 2013) | 0.39 |
| " In addition, trials examining a flexible dosing regimen of insulin degludec in patients with type 1 or 2 diabetes show the potential for adjusting the injection time, without compromising glycaemic control or safety." | ( Insulin degludec and insulin degludec/insulin aspart: a review of their use in the management of diabetes mellitus.
Keating, GM, 2013) | 2.07 |
| "The concentration-time profiles of IDeg U100 and IDeg U200 were similar, and a post-hoc analysis showed bioequivalence between these formulations, as the 90 % confidence intervals (CIs) of the U200/U100 ratios for area under the steady-state serum IDeg concentration-time curve during a dosing interval (τ; 0-24 h) (AUCτ,SS,IDeg) (0." | ( A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec.
Adrian, CL; Deller, S; Haahr, H; Koehler, G; Korsatko, S; Mader, JK; Neubauer, K; Pieber, TR; Thomsen, H, 2013) | 0.59 |
| "Insulin degludec (IDeg) is a new basal insulin in development with a flat, ultra-long action profile that may permit dosing using a simplified titration algorithm with less frequent self-measured blood glucose (SMBG) measurements and more simplified titration steps than currently available basal insulins." | ( Insulin degludec once-daily in type 2 diabetes: simple or step-wise titration (BEGIN: once simple use).
Brod, M; Niemeyer, M; Ocampo Francisco, AM; Philis-Tsimikas, A; Rothman, J, 2013) | 3.28 |
| " A number of new, long-acting basal insulins are in development that provide good metabolic control, but with a lower risk of hypoglycaemia than currently available insulins, and greater flexibility in dosing time from day to day." | ( Insulin degludec--the impact of a new basal insulin on care in type 2 diabetes.
Cos, X; Khunti, K; Rutten, G, 2014) | 1.85 |
| " Pharmacokinetic endpoints included the total exposure of IDeg, ie the area under the IDeg serum concentration curve during one dosing interval at steady state (AUC(IDeg,τ,SS)) (τ = 0-24 h, equal to one dosing interval) and the maximum IDeg serum concentration at steady state (C(max,IDeg,SS))." | ( Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitus.
Deller, S; Glettler, K; Haahr, H; Hastrup, H; Koehler, G; Korsatko, S; Mader, JK; Pieber, TR; Søndergaard, F; Treiber, G; Urschitz, M; Wolf, M, 2014) | 0.67 |
| " Mean AUC(IDeg,0-12h,SS)/AUC(IDeg,τ,SS) was 53 % in both younger adult and elderly subjects, showing that in both age groups IDeg exposure was evenly distributed across the first and second 12 h of the 24-hour dosing interval." | ( Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitus.
Deller, S; Glettler, K; Haahr, H; Hastrup, H; Koehler, G; Korsatko, S; Mader, JK; Pieber, TR; Søndergaard, F; Treiber, G; Urschitz, M; Wolf, M, 2014) | 0.67 |
| "The exposure of IDeg at steady state during once-daily dosing was similar in younger adult and elderly subjects." | ( Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitus.
Deller, S; Glettler, K; Haahr, H; Hastrup, H; Koehler, G; Korsatko, S; Mader, JK; Pieber, TR; Søndergaard, F; Treiber, G; Urschitz, M; Wolf, M, 2014) | 0.67 |
| " Simulated steady-state insulin degludec pharmacokinetic profiles showed an even distribution of exposure across a 24-h dosing interval regardless of hepatic function status." | ( Insulin degludec: pharmacokinetic properties in subjects with hepatic impairment.
Arold, G; Haahr, H; Højbjerre, M; Klim, S; Kupčová, V; Roepstorff, C, 2014) | 2.15 |
| "4 U/kg IDeg or insulin glargine (IGlar), respectively, on two separate dosing visits, with pharmacokinetic blood sampling up to 72-h postdose." | ( Insulin degludec's ultra-long pharmacokinetic properties observed in adults are retained in children and adolescents with type 1 diabetes.
Aschemeier, B; Biester, T; Blaesig, S; Danne, T; Granhall, C; Haahr, H; Kordonouri, O; Kristensen, NR; Remus, K; Søndergaard, F, 2014) | 1.85 |
| " Patients were allocated randomly to a sequence of 2 treatment periods, separated by a 7- to 21-day washout period, with once-daily IDeg or insulin detemir dosing for 6 days at a predefined fixed dose level (0." | ( Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type 2 diabetes mellitus.
Haahr, H; Hompesch, M; Morrow, L; Roepstorff, C; Thomsen, HF; Watkins, E, 2014) | 0.66 |
| "The inferior glycaemic control and increased risk of hypoglycaemia with IDeg 3TW compared with IGlar OD do not support a three-times-weekly dosing regimen." | ( Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials.
Bode, B; DeVries, JH; Johansen, T; Leiter, LA; Moses, A; Ratner, R; Russell-Jones, D; Zinman, B, 2013) | 0.7 |
| " In addition, when dosing intervals vary substantially from day to day, degludec continues to be effective and to maintain a low rate of nocturnal hypoglycemia." | ( Insulin degludec, a long-acting once-daily basal analogue for type 1 and type 2 diabetes mellitus.
Berard, L; MacNeill, G, 2015) | 1.86 |
| " The pharmacokinetic profile of IDeg demonstrates an even distribution of exposure across one dosing interval." | ( A review of the pharmacological properties of insulin degludec and their clinical relevance.
Haahr, H; Heise, T, 2014) | 0.66 |
| " Clinical trials have shown that this ultra long-acting insulin analogue administered in a flexible dosage treatment, reached a good glycaemic control with no increase on hypoglycemia risk." | ( [Therapeutic compliance and flexibility in the use of basal insulins].
Costa Gil, JE; Faingold, MC; Fuente, GV; Litwak, LE, 2014) | 0.4 |
| " In once-daily dosing regimen it reaches steady state after approximately 3 days." | ( Translating structure to clinical properties of an ideal basal insulin.
Bantwal, G; Sahay, RK; Unnikrishnan, AG, 2014) | 0.4 |
| " In addition, trials examining a flexible dosing regimen of insulin degludec in patients with type 1 or 2 diabetes show the potential for adjusting the injection time, without compromising glycaemic control or safety." | ( Treating to target in type 2 diabetes: the BEGIN trial programme.
Chowdhury, S; Rao, PV; Wangnoo, SK, 2014) | 0.64 |
| " oral therapy and also the flexible dosing options." | ( Efficacy without barriers to insulin therapy: lessons from the BEGIN trial programme.
Jain, SM; Kumar, A; Kumar, H; Mithal, A, 2014) | 0.4 |
| " It is potentially dangerous and the fear of hypoglycaemia may lead to sub-optimal dosing and inadequate glycaemic control." | ( Understanding the safety of the new ultra long acting basal insulin.
Gupta, V; Kalra, S; Kesavadev, J; Ramachandran, A, 2014) | 0.4 |
| "This may enable for a more flexible daytime dosing versus up to now available basal insulins." | ( [Daytime flexible application of Insulin degludec in patients with type 1 diabetes or type 2 diabetes].
Jaeckel, E; Lüdemann, J; Milek, K; Segner, A; Wilhelm, B, 2014) | 0.68 |
| " Both phase 3 studies compared a daytime flexible dosing of IDeg (IDeg-flex) with IDeg at the evening meal (IDeg-evening) and IDler at a fixed daytime." | ( [Daytime flexible application of Insulin degludec in patients with type 1 diabetes or type 2 diabetes].
Jaeckel, E; Lüdemann, J; Milek, K; Segner, A; Wilhelm, B, 2014) | 0.68 |
| "This may enable for a more flexible daytime dosing versus up to now available basal insulins." | ( [Daytime flexible application of Insulin degludec in patients with type 1 diabetes or type 2 diabetes].
Jaeckel, E; Lüdemann, J; Milek, K; Segner, A; Wilhelm, B, 2014) | 0.68 |
| " Both phase 3 studies compared a daytime flexible dosing of IDeg (IDeg-flex) with IDeg at the evening meal (IDeg-evening) and IDler at a fixed daytime." | ( [Daytime flexible application of Insulin degludec in patients with type 1 diabetes or type 2 diabetes].
Jaeckel, E; Lüdemann, J; Milek, K; Segner, A; Wilhelm, B, 2014) | 0.68 |
| " The recent approval of insulin degludec/liraglutide administered in a fixed ratio combination is unique not simply for the additive benefits of the two agents, but because it now permits adjustable dosing of liraglutide together with insulin, providing better glucose control than with either agent alone at lower dose levels." | ( First fixed-ratio combination of insulin degludec and liraglutide for the treatment of type 2 diabetes.
Rendell, M, 2015) | 1.01 |
| "The limitations of current basal insulin preparations include concerns related to their pharmacokinetic and pharmacodynamic properties, hypoglycaemia, weight gain, and perception of management complexity, including rigid dosing schedules." | ( Clinical use of insulin degludec.
Cariou, B; Evans, M; Gross, JL; Harris, S; Landstedt-Hallin, L; Meneghini, L; Mithal, A; Rodriguez, MR; Vora, J, 2015) | 0.76 |
| " Liraglutide exposure was lower when dosed as IDegLira but met the criterion for equivalence." | ( Preserved pharmacokinetic exposure and distinct glycemic effects of insulin degludec and liraglutide in IDegLira, a fixed-ratio combination therapy.
Bode, B; Ingwersen, SH; Jacobsen, LV; Kapitza, C; Poulsen, P, 2015) | 0.65 |
| " The evenly distributed glucose-lowering effect of IDeg was confirmed by the AUCGIR across one dosing interval, as each of the four 6-h intervals across one dosing interval contributed ∼ 25% of the AUCGIR,τ,SS." | ( Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
Bøttcher, SG; Haahr, H; Heise, T; Hermanski, L; Hövelmann, U; Nosek, L, 2015) | 0.65 |
| " Exposure and glucose-lowering effects are more stable and evenly distributed across one dosing interval for IDeg versus IGlar (Clinical trials." | ( Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
Bøttcher, SG; Haahr, H; Heise, T; Hermanski, L; Hövelmann, U; Nosek, L, 2015) | 0.65 |
| "8 mg in combination with metformin (≥1500 mg) were randomized to addition of once-daily IDeg ('IDeg add-on to liraglutide' arm; n = 174) or placebo ('placebo add-on to liraglutide' arm; n = 172), with dosing of both IDeg and placebo based on titration guidelines." | ( Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study).
Andersen, TH; Aroda, VR; Bailey, TS; Cariou, B; Kumar, S; Leiter, LA; Philis-Tsimikas, A; Raskin, P; Zacho, J, 2016) | 0.77 |
| " At steady state, total glucose-lowering effect (area under the glucose infusion rate [GIR] curve during one dosing interval [τ, 0-24 h] at steady state [AUCGIR ,τ, SS]) was 1,446 mg/kg and total exposure (geometric mean) of IDeg (AUCID eg,τ, SS) was 81,270 pmol h/L." | ( Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patients.
Bardtrum, L; Haahr, H; Hirao, K; Ikushima, I; Kaku, K, 2016) | 0.69 |
| " These data support once-daily dosing of IDeg in all patients." | ( Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patients.
Bardtrum, L; Haahr, H; Hirao, K; Ikushima, I; Kaku, K, 2016) | 0.69 |
| " The characteristics of the GIR profile for IDegAsp were retained when simulated to steady state in a twice-daily dosing regimen." | ( Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose-lowering effects.
Bardtrum, L; Haahr, H; Ikushima, I; Sasaki, T, 2016) | 1.88 |
| "This was a 26-week, multicenter, open-label, randomized, treat-to-target trial, with a 2 × 2 factorial design comparing IDeg flexible (allowing dosing ±8 h from an agreed dosing time) with IDeg fixed dosing (at the same time each day)." | ( Efficacy and safety of once-daily insulin degludec dosed flexibly at convenient times vs fixed dosing at the same time each day in a Japanese cohort with type 2 diabetes: A randomized, 26-week, treat-to-target trial.
Hersløv, ML; Hyllested-Winge, J; Jinnouchi, H; Kadowaki, T; Kaku, K; Nakamura, S, 2016) | 0.71 |
| "The majority of doses were taken within 2 h of the agreed dosing time, showing a high level of adherence among Japanese patients." | ( Efficacy and safety of once-daily insulin degludec dosed flexibly at convenient times vs fixed dosing at the same time each day in a Japanese cohort with type 2 diabetes: A randomized, 26-week, treat-to-target trial.
Hersløv, ML; Hyllested-Winge, J; Jinnouchi, H; Kadowaki, T; Kaku, K; Nakamura, S, 2016) | 0.71 |
| "These results showed the efficacy and safety of allowing patients to vary the time they dosed IDeg, when necessary, in Japanese patients with type 2 diabetes." | ( Efficacy and safety of once-daily insulin degludec dosed flexibly at convenient times vs fixed dosing at the same time each day in a Japanese cohort with type 2 diabetes: A randomized, 26-week, treat-to-target trial.
Hersløv, ML; Hyllested-Winge, J; Jinnouchi, H; Kadowaki, T; Kaku, K; Nakamura, S, 2016) | 0.71 |
| "In people with T2DM, once- and twice-daily dosing provides similar overall glycaemic control (HbA1c ) to current modern insulins, but with lower risk of nocturnal hypoglycaemia." | ( Clinical use of the co-formulation of insulin degludec and insulin aspart.
Arechavaleta, R; Awata, T; Bain, SC; Ceriello, A; Christiansen, JS; Fulcher, GR; Gonzalez-Gálvez, G; Hirose, T; Home, PD; Kaku, K; Kumar, A; Litwak, L; Madsbad, S; Mehta, R; Mithal, A; Pinget, M; Tambascia, M; Tibaldi, J; Unnikrishnan, AG, 2016) | 0.71 |
| " Indeed, NPH insulin remains widely used today despite a frequent need for a twice-daily dosing and a relatively high incidence of hypoglycaemia." | ( Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes.
Heise, T; Mathieu, C, 2017) | 0.46 |
| " The glucose-lowering effect profile of IDegAsp during once-daily dosing at steady state shows distinct and clearly separated action from the prandial and basal components of IDegAsp." | ( A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use.
Fita, EG; Haahr, H; Heise, T, 2017) | 0.83 |
| " The day-to-day variability in glucose-lowering effect assessed in 2-hour intervals was consistently low with IDeg over 24 hours, but steadily increased with IGlar-U300 to a maximum at 10 to 12 hours and 12 to 14 hours after dosing (variance ratios 12." | ( Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes.
Famulla, S; Haahr, HL; Heise, T; Kaplan, K; Nosek, L; Nørskov, M, 2017) | 1.9 |
| " Despite glycated haemoglobin concentrations being lower with IDegLira at end of treatment, confirmed and nocturnal-confirmed hypoglycaemia rates were lower for IDegLira vs IDeg and IGlar U100, irrespective of dosing time." | ( Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used.
Chen, R; Heller, S; Jaeckel, E; Jarlov, H; Lehmann, L; Lingvay, I; Norwood, P, 2017) | 0.7 |
| "Treatment with IDegLira, vs IDeg and IGlar U100, resulted in lower rates of hypoglycaemia regardless of dosing time and definition of hypoglycaemia used." | ( Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used.
Chen, R; Heller, S; Jaeckel, E; Jarlov, H; Lehmann, L; Lingvay, I; Norwood, P, 2017) | 0.7 |
| "Patients were randomized 1:1 to receive once-daily insulin degludec followed by insulin glargine U100 (n = 249) or to receive insulin glargine U100 followed by insulin degludec (n = 252) and randomized 1:1 to morning or evening dosing within each treatment sequence." | ( Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial.
Bailey, TS; Gerety, G; Gumprecht, J; Hansen, CT; Lane, W; Nielsen, TSS; Philis-Tsimikas, A; Warren, M, 2017) | 1.11 |
| "Patients were randomized 1:1 to receive once-daily insulin degludec followed by insulin glargine U100 (n = 361) or to receive insulin glargine U100 followed by insulin degludec (n = 360) and randomized 1:1 to morning or evening dosing within each treatment sequence." | ( Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial.
Bhargava, A; Chaykin, L; de la Rosa, R; Handelsman, Y; Kvist, K; Norwood, P; Troelsen, LN; Wysham, C, 2017) | 1.11 |
| "38) was similar for both dosing schemes." | ( Reduction in insulin degludec dosing for multiple exercise sessions improves time spent in euglycaemia in people with type 1 diabetes: A randomized crossover trial.
Aberer, F; Birnbaumer, P; Bracken, RM; Dietz, P; Eckstein, ML; Hofmann, P; Holler, P; Koehler, G; Kojzar, H; Moser, O; Mueller, A; Pferschy, P; Simi, H; Sourij, C; Sourij, H, 2019) | 0.88 |
| "0001), and more even dosing over each 6-h quartile, with insulin degludec 200 U/mL versus insulin glargine 300 U/mL (0." | ( Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation.
Bolli, GB; Fanelli, CG; Owens, DR; S Bailey, T; Yale, JF, 2019) | 0.99 |
| "The stable, ultra-long duration of action of insulin degludec (degludec) minimizes fluctuations in glucose-lowering activity over the daily (24-h) dosing period, and comparative studies with other basal insulins suggest that these properties translate into a lower risk of hypoglycemia at equivalent levels of glycemic control." | ( Switching "Real-World" Diabetes Patients to Degludec from Other Basal Insulins Provides Different Clinical Benefits According to Their Baseline Glycemic Control.
Haldrup, S; Knudsen, ST; Lapolla, A; Schultes, B; Tentolouris, N; Wolden, ML, 2019) | 0.77 |
| " Multiple randomized control trials and real-world evidence studies have demonstrated that the newer second-generation basal insulin analogs, insulin glargine 300 units/mL and insulin degludec 100 or 200 units/mL, provide stable glycemic control with once-daily dosing and are associated with a reduced risk of hypoglycemia compared with previous-generation basal insulin analogs insulin glargine 100 units/mL and insulin detemir." | ( Differentiating Basal Insulin Preparations: Understanding How They Work Explains Why They Are Different.
Cheng, AYY; Patel, DK; Reid, TS; Wyne, K, 2019) | 0.71 |
| " At 12 months, HbA1c, fasting plasma glucose (FPG), and basal insulin dosage decreased significantly." | ( Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective Study.
de Valk, HW; Fadini, GP; Feher, M; Hansen, TK; Jendle, J; Koefoed, MM; Wolden, M; Zimmermann, E, 2019) | 0.51 |
| " We present results from 4 nonclinical rat studies evaluating effects of repeated dosing with insulin detemir (≤26 weeks) or degludec (52 weeks) in mammary glands." | ( Evaluation of Cell Proliferation in Rat Mammary Glands Is Not Predictive of the Carcinogenic Potential of Insulin In Vivo.
Brinck, PR; Jensen, VFH; Mølck, AM; Nowak, J; Sjögren, I; Thorup, I, ) | 0.13 |
| "Patients with inadequate glycemic control or who find their basal insulin dosing inconvenient may benefit from switching to Ideg, with the potential for small improvementa in A1C at lower basal insulin doses." | ( Clinical Utility of Switching to Insulin Degludec From Other Basal Insulins in Adult Patients With Type 1 or Type 2 Diabetes.
Bakal, JA; Baran, O; Dersch-Mills, D; Hnatiuk, M; Huyghebaert, T; Roedler, RL, 2022) | 1 |
| "Once-weekly insulin icodec could provide a simpler dosing alternative to daily basal insulin in people with type 2 diabetes." | ( Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial.
Asong, M; Desouza, C; Gourdy, P; Kar, S; Lingvay, I; Mu, Y; Vianna, A; Vilsbøll, T; Vinther, S, 2023) | 1.18 |